<DOC>
	<DOC>NCT00690573</DOC>
	<brief_summary>To evaluate efficacy, safety and pharmacokinetics of adalimumab in Japanese children with Polyarticular Juvenile Rheumatoid Arthritis</brief_summary>
	<brief_title>Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis</brief_title>
	<detailed_description>This was an open-label long-term study that was completed following study drug approval in Japan for the treatment of JRA. Data are presented through Week 144 and for the final visit.</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Arthritis, Juvenile</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Inclusion Criteria Diagnosis of polyarticular juvenile rheumatoid arthritis (JRA) according to the criteria of the American College on Rheumatology (ACR) Disease activity inadequately controlled by nonsteroidal antiinflammatory drugs (NSAIDs) or methotrexate (MTX) Presence at screening of at least 5 swollen joints (not due to deformity) and at least 3 joints with limitation of passive motion with pain by passive motion or/and pain by pressure (tenderness) Stable dosage of MTX for at least 12 weeks prior to the screening visit or discontinuation of MTX at least 14 days prior to baseline visit (Day 1) Discontinuation of diseasemodifying antirheumatic drugs (DMARDs) other than MTX at least 28 days before screening visit Exclusion Criteria History of inflammatory joint disease other than JRA Functional class IV JRA by ACR criteria Clinically significant cardiac disease or laboratory abnormalities Any subject who is considered by the investigator, for any reason, to be an unsuitable candidate for the study</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Juvenile Rheumatoid Arthritis</keyword>
</DOC>